Principia biopharma inc. (PRNB)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Sep'17
Revenue

30,000

35,160

61,297

79,861

62,848

69,137

44,512

0

0

0

Operating expenses:
Research and development

85,302

74,083

66,287

57,119

47,295

40,533

32,916

0

0

0

General and administrative

22,703

19,842

18,903

16,825

13,814

11,462

8,594

0

0

0

Total operating expenses

108,005

93,925

85,190

73,944

61,109

51,995

41,510

0

0

0

Loss from operations

-78,005

-58,765

-23,893

5,917

1,739

17,142

3,002

0

0

0

Other income, net

-1

0

-35

-171

-315

-653

-382

0

0

0

Interest income

5,402

4,973

4,437

3,742

2,746

1,678

0

0

0

-

Net loss

-72,604

-53,792

-19,491

9,488

4,170

18,167

1,665

0

0

0

Net loss per share, basic and diluted

-0.99

-

-

-

-0.57

-

-

-

-

-

Weighted-average shares used to calculate net loss per share, basic and diluted

32,993

-

-

-

23,866

-

-

-

-

-

Interest expense

-

-

-

-

-

-

-

-

-

0

Net income (loss) attributable to common stockholders

-

-

-23,951

-1,655

-

4,917

0

0

0

-

Net income (loss) per share attributable to common stockholders
Basic

-

-

-0.93

0.30

-

0.65

0.00

0.00

0.00

-12.26

Diluted

-

-

-0.93

0.28

-

0.57

0.00

0.00

0.00

-12.26

Weighted-average shares used to calculate net income (loss) per share attributable to common stockholders
Basic

-

-

24,018

23,927

-

24,090

5,087

681

630

581

Diluted

-

-

24,018

25,792

-

25,781

6,144

1,412

1,170

581